Neogenomics reported total revenue of $209 million, up 11% year over year, ahead of its expectations of approximately 10% growth. It raised full-year revenue guidance to $807 to $809 million from $802 to $806 million, and adjusted EBITDA guidance to approximately 60 million from 56 to 58 million. Warren Stone becomes chief executive officer effective January 4, 2027, succeeding Tony Zook, who becomes executive chair.
NEO · Neogenomics Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
NeoGenomics, Inc. reported that revenue for the three and nine months ended September 30, 2026 increased $21.5 million, or 11.4%, and $60.4 million, or 11.2%, respectively, versus 2025. Gross profit margin was 46.2% and 45.1%, respectively, compared with 42.8% and 43.0%.
NeoGenomics reported third-quarter 2026 revenue up 11% to $209 million. It raised full-year 2026 revenue guidance to $807 million to $809 million and expects adjusted EBITDA of approximately $60 million. Warren Stone, President and COO, will become CEO effective January 4, 2027.
NeoGenomics appointed Warren Stone CEO and a director effective January 4, 2027, while Tony Zook will become Executive Chairman. Preliminary third-quarter revenue is approximately $209 million, with NGS revenue growth of approximately 28%, and full-year revenue guidance is expected to rise.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 28, 2026TL;DR. NeoGenomics delivered 11% total revenue growth, 13% clinical revenue growth, 29% NGS growth and 310-basis-point adjusted gross-margin expansion, while raising full-year revenue and adjusted EBITDA guidance and adding a third Medicare-covered RaDaR ST indication. Non-clinical declines, lower cash, temporary receivables pressure, reimbursement-rate exposure, unreimbursed MRD testing and an $8 million GAAP net loss remain the principal headwinds.
- + Third-quarter total revenue increased 11% to $209 million.
- + Clinical revenue increased 13% to $195 million, driven by 29% NGS revenue growth.
- + Full-year 2026 revenue guidance was raised to $807-$809 million from $802-$806 million.
- + Full-year 2026 adjusted EBITDA guidance was raised to approximately $60 million from $56-$58 million.
- + Adjusted gross margin expanded 310 basis points to 49%, with adjusted EBITDA of $19 million.
- + RaDaR ST received Medicare coverage for immunotherapy treatment-response monitoring, marking its third covered indication.
- − Non-clinical revenue declined approximately 10%, or $1.5 million year over year, creating a headwind to total revenue growth.
- − Cash and cash equivalents were $139 million, down $6 million from the prior quarter.
- − The revenue-cycle-management platform transition temporarily affected receivables, with normalization expected through the fourth quarter and into early 2027.
- − Preliminary 2027 reimbursement rates create a low-to-mid-single-digit-million exposure that flows through gross margin and EBITDA.
- − Unreimbursed MRD testing was expected to remain a gross-margin headwind in the near term.
- − The company reported a third-quarter GAAP net loss of $8 million.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| NGS revenue growth | 28% | Q3 2026 | — |
| Adjusted EBITDA non-GAAP | $14.47M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NEO
this stock
Neogenomics Inc
|
$1.98B | +30.0% | +10.1% | — | 10.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$256.67B | +19.6% | +14.5% | 36.5 | 1.3% |
|
DHR
Danaher Corp
|
$160.81B | -0.1% | +8.5% | 37.4 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.03B | +3.2% | +10.4% | 47.1 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.99B | +30.3% | +6.4% | 34.9 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 28, 2026
- This year
- 24
NeoGenomics, Inc. reported that revenue for the three and nine months ended September 30, 2026 increased $21.5 million, or 11.4%, and $60.4 million, or 11.2%, respectively, versus 2025. Gross profit margin was 46.2% and 45.1%, respectively, compared with 42.8% and 43.0%.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NEO | -9.2% | -10.3% | +45.3% | -12.0% | +30.0% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -5.3% | -4.7% | +48.8% | -8.7% | +22.9% |